[{"orgOrder":0,"company":"Tr1X Bio","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cell & Gene Therapy","year":"2024","type":"Inapplicable","leadProduct":"TRX103","moa":"Treg cell","graph1":"Oncology","graph2":"Phase I","graph3":"Tr1X Bio","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Tr1X Bio \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Tr1X Bio \/ Undisclosed"},{"orgOrder":0,"company":"Tr1X Bio","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Cell & Gene Therapy","year":"2024","type":"Inapplicable","leadProduct":"TRX103","moa":"Treg cell","graph1":"Immunology","graph2":"Phase I","graph3":"Tr1X Bio","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Tr1X Bio \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Tr1X Bio \/ Undisclosed"},{"orgOrder":0,"company":"Tr1X Bio","sponsor":"California Institute for Regenerative Medicine","pharmaFlowCategory":"D","therapeuticArea":"Immunology","country":"U.S.A","productType":"Cell & Gene Therapy","year":"2025","type":"Funding","leadProduct":"TRX103","moa":"Treg cell","graph1":"Immunology","graph2":"Phase I","graph3":"Tr1X Bio","amount2":0.01,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Immunology","amount2New":0.01,"dosageForm":"Infusion","sponsorNew":"Tr1X Bio \/ California Institute for Regenerative Medicine","highestDevelopmentStatusID":"6","companyTruncated":"Tr1X Bio \/ California Institute for Regenerative Medicine"},{"orgOrder":0,"company":"Tr1X Bio","sponsor":"The Column Group","pharmaFlowCategory":"D","therapeuticArea":"Immunology","country":"U.S.A","productType":"Cell & Gene Therapy","year":"2024","type":"Series A Financing","leadProduct":"TRX103","moa":"Treg cell","graph1":"Immunology","graph2":"Phase I","graph3":"Tr1X Bio","amount2":0.080000000000000002,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Immunology","amount2New":0.080000000000000002,"dosageForm":"Infusion","sponsorNew":"Tr1X Bio \/ The Column Group","highestDevelopmentStatusID":"6","companyTruncated":"Tr1X Bio \/ The Column Group"},{"orgOrder":0,"company":"Tr1X Bio","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Cell & Gene Therapy","year":"2024","type":"Inapplicable","leadProduct":"TRX103","moa":"Treg cell","graph1":"Immunology","graph2":"Phase I\/ Phase II","graph3":"Tr1X Bio","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Tr1X Bio \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Tr1X Bio \/ Undisclosed"},{"orgOrder":0,"company":"Tr1X Bio","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Cell & Gene Therapy","year":"2024","type":"Inapplicable","leadProduct":"TRX103","moa":"Treg cell","graph1":"Immunology","graph2":"Phase I\/ Phase II","graph3":"Tr1X Bio","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Tr1X Bio \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Tr1X Bio \/ Undisclosed"},{"orgOrder":0,"company":"Tr1X Bio","sponsor":"Undisclosed","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"U.S.A","productType":"Cell & Gene Therapy","year":"2025","type":"Financing","leadProduct":"TRX319","moa":"CD19","graph1":"Neurology","graph2":"IND Enabling","graph3":"Tr1X Bio","amount2":0.050000000000000003,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Neurology","amount2New":0.050000000000000003,"dosageForm":"Undisclosed","sponsorNew":"Tr1X Bio \/ Undisclosed","highestDevelopmentStatusID":"5","companyTruncated":"Tr1X Bio \/ Undisclosed"}]

Find Clinical Drug Pipeline Developments & Deals by Tr1X Bio

Menu
Xls
Filters Filter
×
FILTER:
filter
Company Name
    filter

    Year

      filter

      DEALS // DEV.

        filter

        Country

          filter
          Sponsor
            filter

            Therapeutic Area

              filter

              Study Phase

                filter

                Deal Type

                  filter

                  Product Type

                    filter

                    Dosage Form

                      filter

                      Lead Product

                        filter

                        Target

                          Loading...

                          Therapeutic Area by Lead Product

                          Study Phase by Lead Product

                          Company by Lead Product

                          Top Deals by Deal Size (USD bn)

                          01

                          AES
                          Not Confirmed
                          AES
                          Not Confirmed

                          Details : The financing for TRX319, a cell & gene therapy targeting CD19, will advance clinical development efforts.

                          Product Name : Undisclosed

                          Product Type : Cell & Gene Therapy

                          Upfront Cash : Undisclosed

                          October 14, 2025

                          Lead Product(s) : TRX319

                          Therapeutic Area : Neurology

                          Highest Development Status : IND Enabling

                          Sponsor : Undisclosed

                          Deal Size : $50.0 million

                          Deal Type : Financing

                          blank

                          02

                          AES
                          Not Confirmed
                          AES
                          Not Confirmed

                          Details : The funding aims to advance the development of TRX103 an engineered Tr1 Treg cell therapy for use in the prevention of GvHD in blood cancer patients undergoing mismatched stem cell transplants.

                          Product Name : Undisclosed

                          Product Type : Cell & Gene Therapy

                          Upfront Cash : Undisclosed

                          April 04, 2025

                          Lead Product(s) : TRX103

                          Therapeutic Area : Immunology

                          Highest Development Status : Phase I

                          Sponsor : California Institute for Regenerative Medicine

                          Deal Size : $8.0 million

                          Deal Type : Funding

                          blank

                          03

                          AES
                          Not Confirmed
                          AES
                          Not Confirmed

                          Details : TRX103 is a Cell and Gene Therapy drug candidate, which is currently being evaluated in phase I/ phase II clinical studies for the treatment of Crohn Disease.

                          Product Name : Undisclosed

                          Product Type : Cell & Gene Therapy

                          Upfront Cash : Inapplicable

                          December 06, 2024

                          Lead Product(s) : TRX103

                          Therapeutic Area : Immunology

                          Highest Development Status : Phase I/ Phase II

                          Sponsor : Undisclosed

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          blank

                          04

                          AES
                          Not Confirmed
                          AES
                          Not Confirmed

                          Details : TRX103, a first-in-class Type 1 Treg cell therapy candidate, which is being evaluated for the treatment of patients with treatment-refractory crohn’s disease.

                          Product Name : Undisclosed

                          Product Type : Cell & Gene Therapy

                          Upfront Cash : Inapplicable

                          August 07, 2024

                          Lead Product(s) : TRX103

                          Therapeutic Area : Immunology

                          Highest Development Status : IND Enabling

                          Sponsor : Undisclosed

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          blank

                          05

                          AES
                          Not Confirmed
                          AES
                          Not Confirmed

                          Details : TRX103, a first-in-class Type 1 Treg cell therapy, is specifically designed for patients with autoimmune and inflammatory disorders, including those undergoing HSCT.

                          Product Name : Undisclosed

                          Product Type : Cell & Gene Therapy

                          Upfront Cash : Inapplicable

                          July 10, 2024

                          Lead Product(s) : TRX103

                          Therapeutic Area : Immunology

                          Highest Development Status : Phase I

                          Sponsor : Undisclosed

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          blank

                          06

                          AES
                          Not Confirmed
                          AES
                          Not Confirmed

                          Details : TRX103 is a Cell and Gene Therapy drug candidate, which is currently being evaluated in phase I clinical studies for the treatment of Hematologic Neoplasms.

                          Product Name : Undisclosed

                          Product Type : Cell & Gene Therapy

                          Upfront Cash : Inapplicable

                          June 17, 2024

                          Lead Product(s) : TRX103

                          Therapeutic Area : Oncology

                          Highest Development Status : Phase I

                          Sponsor : Undisclosed

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          blank

                          07

                          AES
                          Not Confirmed
                          AES
                          Not Confirmed

                          Details : The net proceeds will be used to bring universal allogeneic regulatory T (Treg), including TRX103 and CAR-Treg cell therapies, TRX301, for autoimmune and inflammatory diseases.

                          Product Name : Undisclosed

                          Product Type : Cell & Gene Therapy

                          Upfront Cash : Undisclosed

                          January 17, 2024

                          Lead Product(s) : TRX103

                          Therapeutic Area : Immunology

                          Highest Development Status : IND Enabling

                          Sponsor : The Column Group

                          Deal Size : $75.0 million

                          Deal Type : Series A Financing

                          blank